miRNA Biomarkers in Multiple Sclerosis

Completed

• Conditions: miRNA; Multiple Sclerosis; Biomarker; Epigenetic
• Interventions: Genetic: miRNA

• Registration Number: NCT04772495
• Lead Sponsor: University of Gaziantep

Brief Summary

Multiple Sclerosis (MS) characterized by demyelination and axonal degeneration is a chronic inflammatory disease of the central nervous system (CNS). Recent studies have shown that dysregulated miRNAs alter immune responses, so they may have roles basis on various genetic diseases such as MS and may be potential targets for biomarkers and new therapeutic approaches. In this study, we evaluated the dysregulation of miRNA expression levels at MS and MS stages. We also discussed the potential of these miRNAs to be biomarkers and/or therapeutic targets in MS.

Detailed Description

Not available

Study Timeline

• Study Start: 2015-05
• Primary Completion: 2017-05
• Study Completion: 2017-07
• Status Verified: 2021-02
• Study First Submitted: 2021-02-23
• Study First Submitted QC: 2021-02-23
• Last Update Submitted: 2021-02-23
• Study First Posted: 2021-02-26
• Last Update Posted: 2021-02-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 69

Inclusion Criteria

• The age of 25 years and above
• at least one Central Nervous System (CNS) demyelination event

Exclusion Criteria

• with genetic diseases, hypertension, head trauma, neuropsychiatric disease, diabetes mellitus, hypertension, cardiac failure, hepatic failure, renal failure, Thalassemia, Sickle cell disease, iron deficiency, and B12 deficiency

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Control group	miRNA	not Multiple sclerosis
Study group	miRNA	with Multiple sclerosis

Primary Outcome Measures

Name	Time	Method
miRNA expression	intraoperative	peripheral blood miRNA expressions